“IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Although we are very encouraged by the clinical and preclinical data that we have generated for the programs we are halting, given the difficult conditions in the capital markets for our industry, we have decided to focus our capital resources on those opportunities that we believe have the most potential to produce significant near-term value. We are very sorry that some of our dedicated and talented employees will be leaving IGM as part of this strategic refocusing, and we wish to extend our sincere thanks and assistance to them in this difficult transition.” As a result of these actions, IGM expects to extend its cash runway into the second quarter of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IGMS:
- IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
- IGM Biosciences price target lowered to $11 from $17 at H.C. Wainwright
- IGM Biosciences price target lowered to $16 from $19 at Wedbush
- IGM Biosciences price target lowered to $25 from $26 at Stifel
- IGM Biosciences price target lowered to $8 from $11 at RBC Capital